BACKGROUND
The impact of the COVID-19 pandemic on health care utilisation and associated costs has been significant, with one in ten patients becoming severely ill and being admitted to hospital with serious complications during the first wave of the pandemic. Risk prediction models can help health care providers identify high-risk patients in their populations and intervene to improve health outcomes and reduce associated costs.
OBJECTIVE
To develop and validate a hospitalisation risk prediction model for adult patients with laboratory confirmed Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
METHODS
The model was developed using pre-linked and standardised data of adult patients with laboratory confirmed SARS-CoV-2 from Cerner’s population health management platform (HealtheIntent®) in the London Borough of Lewisham. A total of 14,203 patients who tested positive for SARS-CoV-2 between 1st March 2020 and 28th February 2021 were included in the development and internal validation cohorts. A second temporal validation cohort covered the period between 1st March 2021 to 30th April 2021. The outcome variable was hospital admission in adult patients with laboratory confirmed SARS-CoV-2. A generalised linear model was used to train the model. The predictive performance of the model was assessed using the area under the receiver operator characteristic curve (ROC-AUC).
RESULTS
Overall, 14,203 patients were included. Of those, 9,755 (68.7%) were assigned to the development cohort, 2,438 (17.2%) to the internal validation cohort, and 2,010 (14.1%) to the temporal validation cohort. A total of 917 (9.4%) patients were admitted to hospital in the development cohort, 210 (8.6%) in the internal validation cohort, and a further 204 (10.1%) in the temporal validation cohort. The model had a ROC-AUC of 0.85 in both the development and validation cohorts. The most predictive factors were older age, male sex, Asian or Other ethnic minority background, obesity, chronic kidney disease, hypertension and diabetes.
CONCLUSIONS
The COVID-19 hospitalisation risk prediction model demonstrated very good performance and can be used to stratify risk in the Lewisham population to help providers reduce unnecessary hospital admissions and associated costs, improve patient outcomes, and target those at greatest risk to ensure full vaccination against SARS-CoV-2. Further research may examine the external validity of the model in other populations.
Risk prediction model for lung cancer incorporating metabolic markers: Development and internal validation in a Chinese population
